logo
  Join        Login             Stock Quote

Epizyme Files For IPO Of Up To $69M

 April 18, 2013 02:26 PM


(By Balachander) Epizyme Inc., a biopharmaceutical company developing therapeutics for the treatment of genetically defined cancers, has filed to raise up to $69 million in an initial public offering (IPO) of its common stock.

The filing with the U.S. federal regulators did not disclose how many shares the Cambridge, Massachusetts-based company plans to offer or the pricing terms.

Epizyme is conducting a Phase 1 clinical trial of its most advanced product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT, for the treatment of mixed lineage rearranged leukemia.

HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression.

In the second quarter of 2013, the company expects to begin a Phase 1/2 clinical trial of its second most advanced product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT, for the treatment of a genetically defined subtype of non-Hodgkin lymphoma.

[Related -Upbeat Forecasts For US Housing Sales In March]

The company expects to use the net proceeds from the offering to fund the costs of Phase 1 clinical development of EPZ-5676, to fund research and development and advance its pipeline of preclinical product candidates and for working capital and general corporate purposes.

For the year ended December 2012, loss attributable to common stockholders was $1.19 million on collaboration revenue of $45.22 million.

The company, which was founded in November 2007, has applied to list its common stock on the NASDAQ under the symbol "EPZM."

Citigroup (C), Cowen and Co. and Leerink Swann are the joint bookrunners on the offering.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageUpbeat Forecasts For US Housing Sales In March

The Fiscal Times advises that the “the housing market is about to perk up.” One of the reasons for the read on...

article imageHappy Birthday, Moore's Law - Pearls of Wisdom for Investors

As Moore’s Law turns 50, we reflect on technology’s incredible history and limitless read on...

article imageIndex Investing Is Not Inherently Socialistic

How does capital get allocated to the public stock read on...

article imageDon't Let Fear of a 'Grexit' Keep You Out of European Stocks

After nearly three years of extremely weak economic growth, the European Central Bank is finally delivering read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Index Investing Is Not Inherently Socialistic
More Articles on: Finance , Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.